Business EconomyPosted at: Oct 14 2025 12:14AM


Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy

Hyderabad, Oct 13 (UNI) Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (OHCM).
Symptomatic obstructive HCM is an often-inherited heart disease that can be a chronic, debilitating and progressive condition where patients may experience symptoms of shortness of breath, dizziness and fatigue as well as serious, life-altering complications, including heart failure, arrhythmias, stroke and in rare cases (~1%) sudden cardiac death.
It affects about 1 in 500 people worldwide, and it is estimated that as many as 2.8 million people in India may be living with the condition; however, 80-90 % patients remain undiagnosed.
Existing medical treatments in India, such as beta blockers, calcium channel blockers, and disopyramide, reduce symptoms but do not address the underlying cause.
Kopozgo is the first in-class disease-specific treatment targeting the core pathophysiological mechanism of obstructive HCM, leading to improvement in functional capacity of heart and symptoms.
Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO) with an import license issued on March 6, 2025.
Kopozgo is now available to patients in India.
The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM.
Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, “With the launch of Kopozgo in India, patients with oHCM now have a promising first-in-class treatment option. This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care for patients in India.”
Globally, mavacamten has been widely recognized, with its first approval granted by the U.S. Food and Drug Administration (FDA) on April 28, 2022, followed by approval from the European union on June 26, 2023.
Since then, the medicine has continued to expand its reach, receiving marketing authorization in more than 50 countries, underscoring its global significance as a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy. UNI KNR SS
Please log in to get detailed story.
Tags: #Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy
More News

Adani Kutch Copper inks deal with caravel for Australian project

09 Nov 2025 | 12:18 AM

Mumbai, Nov 7 (UNI) Adani Group's Kutch Copper Ltd has officially announced that it has signed a non-binding memorandum of understanding (MoU) with Australia's Caravel Minerals Ltd to collaborate on the latter's copper project in Western Australia. According to the deal, Adani-owned Kutch Copper will have the first rights to participate at the project-level or as direct equity investments during the MoU term.

see more..

Tractor, tiller sales soar post-GST: VST CEO

08 Nov 2025 | 10:58 PM

By BD Narayankar
Bengaluru, Nov 8 (UNI) The recent reduction of GST on smaller farm machinery from 12% to 5% has given a strong boost to rural mechanisation, making tractors and power tillers more affordable for small and marginal farmers, VST Tillers Tractors Ltd CEO Anthony Cherukara said.

see more..

JSW Cement posts Q2FY26 net profit of Rs 75 cr

08 Nov 2025 | 8:27 PM

Mumbai, Nov 8 (UNI) JSW Cement has officially announced that it has posted an adjusted profit after tax (PAT) at Rs 75.4 crore in Q2FY26, compared with a loss of Rs 39.9 crore in Q2 FY25.

see more..

India’s housing market to see 5-10 pc annual price rise: Report

08 Nov 2025 | 6:30 PM

New Delhi, Nov 8 (UNI) Housing prices in India are expected to rise by 5-10 pc annually over the next few years, said a report of Confederation of Indian Industry (CII) and Colliers.

see more..

Google introduces ‘Ironwood,’ its most powerful AI chip till now

08 Nov 2025 | 5:44 PM

New Delhi, Nov 8 (UNI) US-based tech giant Google launched 'Ironwood', which is its seventh-generation most powerful Tensor Processing Unit (TPU), a Google blog said.

see more..